Michael Singer, MD

In this Healio Video Perspective from the ASRS meeting, Michael A. Singer, MD, of the University of Texas Health Science Center in San Antonio, discusses topline results for MCO-010 for the treatment of retinitis pigmentosa.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Michael Singer, MD, of the University of Texas Health Science Center, discusses 36-month data investigating Yutiq for chronic noninfectious uveitis.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Michael Singer, MD, discusses a phase 2a study on ANXV in treatment-naive patients with retinal vein occlusion.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Michael Singer, MD, discusses a study that investigated the durability of suprachoroidal triamcinolone acetonide for uveitic macular edema.

In this Healio Video Perspective from the Macula Society meeting, Michael A. Singer, MD, presents real-world data investigating Xipere for the treatment of uveitic macular edema.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Michael A. Singer, MD, presents data on dosing intervals for faricimab as a treatment for wet age-related macular degeneration and diabetic macular edema.

In this Healio Video Perspective from the Vit-Buckle Society meeting, Michael A. Singer, MD, discusses the results of the phase 2 ENVISION trial investigating UBX1325 for the treatment of wet age-related macular degeneration.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Michael A. Singer, MD, discusses phase 3 data from the PALADIN study.

In this Healio/OSN Video Perspective from ASRS 2021, Michael Singer, MD, discusses phase 2 results from a study investigating AR-1105, a dexamethasone intravitreal implant for the treatment of patients with retinal vein occlusion.

In this Healio Video Perspective from the virtual ARVO meeting, Michael Singer, MD, discusses increase in IOP viewed as a “24-month snapshot” in the completer data of the PALADIN study.